Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Ginger—An Herbal Medicinal Product with Broad Anti-Inflammatory Actions
2005 Standout
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
2010
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
2010
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
2013
Osteoarthritis year in review 2019: epidemiology and therapy
2020 Standout
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)
2015
In situ click chemistry generation of cyclooxygenase-2 inhibitors
2017 Standout
Selective Cyclooxygenase-2 Inhibition by Nimesulide in Man
1998
Clinical Pharmacokinetics of Nimesulide
1998
Novel Neurokinin-1 Antagonists as Antiemetics for the Treatment of Chemotherapy-Induced Emesis
2006
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
2004 Standout
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
2009
Therapeutic potential of resveratrol: the in vivo evidence
2006 Standout
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines
2008 Standout
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study
2007
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial
2008
Optimising antiemetic therapy: what are the problems and how can they be overcome?
2005
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)
2003 Standout
Risk?benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting
2004
A Randomized, Double-Blind Study of Granisetron Plus Dexamethasone Versus Ondansetron Plus Dexamethasone to Prevent Postoperative Nausea and Vomiting in Patients Undergoing Abdominal Hysterectomy
2005
New antiemetic drugs
2006
Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study
2010
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
2014
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
2007
Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial
2011
Palonosetron Hydrochloride Is an Effective and Safe Option to Prevent Chemotherapy-induced Nausea and Vomiting in Children
2008
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
2005 Standout
Randomized, placebo‐controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting
2008
5-Hydroxytryptamine3receptor antagonists and cardiac side effects
2014
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
2005 Standout
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
2014
Cancer-associated cachexia
2018 Standout
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)
2015
Platelet Activation and Atherothrombosis
2007 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Pharmacological targeting of the HIF hydroxylases – A new field in medicine development
2016 StandoutNobel
Coxibs and Cardiovascular Disease
2004 Standout
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Three Different Doses of Palonosetron Versus Placebo for Preventing Postoperative Nausea and Vomiting
2008
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Consensus Guidelines for the Management of Postoperative Nausea and Vomiting
2013 Standout
Improving the quality of reporting of randomized controlled trials. The CONSORT statement
1996 Standout
Different Doses of Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Children Undergoing Strabismus Surgery
2011
Phytochemistry of Cannabis sativa L.
2017 Standout
Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis
1998
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study
2008
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study
2005
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
2010
Cisplatin: The first metal based anticancer drug
2019 Standout
Pelvic Inflammatory Disease: Metaanalysis of Antimicrobial Regimen Efficacy
1993
Sexually transmitted diseases treatment guidelines
2003 Standout
Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial
2001 Standout
In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview
1997
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
2001
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Neurodegenerative diseases and oxidative stress
2004 Standout
Oxidative stress and neurodegeneration: where are we now?
2006 Standout
A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy
2009
Nimesulide in Dysmenorrhoea
1993
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling
2006
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials
2014
New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes
2001
Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy
2005
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
2005
A comparative study between palonosetron and granisetron to prevent postoperative nausea and vomiting after laparoscopic cholecystectomy.
2010
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy
2009
Inorganic nanoparticles in porous coordination polymers
2016 StandoutNobel
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
2001 StandoutScience
Challenges of Evaluating the Cardiac Effects of Anticancer Agents
2006
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial
2000
New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron
2005
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
2006
Oxidative Stress: An Essential Factor in the Pathogenesis of Gastrointestinal Mucosal Diseases
2014 Standout
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting
2007
Randomized Controlled Trial of 3 vs 10 Days of Trimethoprim/Sulfamethoxazole for Acute Maxillary Sinusitis
1995
Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis
2018
Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions
1999
Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
2007
Risk–benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting
2004
Cannabinoids for Medical Use
2015 Standout
Clinical practice guideline: Adult sinusitis
2007 Standout
Antioxidants as treatment for neurodegenerative disorders
2002
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines.
2000 Standout
Anthraquinones As Pharmacological Tools and Drugs
2016 Standout
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of A. Macciocchi being referenced
DOUBLE‐BLIND STUDY COMPARING THE LONG‐TERM EFFICACY OF THE COX‐2 INHIBITOR NIMESULIDE AND NAPROXEN IN PATIENTS WITH OSTEOARTHRITIS
2001
Renal Effects of Nimesulide in Furosemide-Treated Subjects
1993
Distribution of oral nimesulide in female genital tissues
1991
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
2006
Controlled Clinical Investigation of Acute Analgesic Activity of Nimesulide in Pain after Oral Surgery
1993
Nimesulide Binding to Components within Blood
1993
Pharmacokinetics, metabolism and excretion of intravenous [l4C]‐palonosetron in healthy human volunteers
2004
Analysis of uterine contractility after administration of the non‐steroidal antiinflammatory drug nimesulide
1992
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
2003
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study
2004
Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist
2003
Acute Salpingitis and Thiamphenicol
1984
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients.
2005
Brodimoprim versus amoxicillin in the treatment of acute sinusitis.
1992
Antioxidant profile of nimesulide, indomethacin and diclofenac in phosphatidylcholine liposomes (PCL) as membrane model.
1993
Double-blind study evaluating by endoscopy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthritic patients.
1994
Gastroduodenal tolerability of nimesulide and diclofenac in patients with osteoarthritis
1998
Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: An active controlled equivalence study
1999
Brodimoprim in Upper Respiratory Tract Infections
1996
Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis.
1994
Palonosetron (PALO) versus ondanestron/dolasetron (OND/DOL) in preventing chemotherapy-induced nausea and vomiting (CINV) in elderly patients: Combined results from 2 phase III trials
2004